Jeffrey Quillen’s varied business law practice focuses on companies involved with advanced technology applications. He serves as outside general counsel to a number of emerging biotechnology, software and information technology companies. For these and other clients he negotiates and drafts agreements regarding intellectual property rights, including patent license agreements with major research universities and collaboration agreements with pharmaceutical companies.
On the financing side, Jeffrey represents venture capital funds and emerging companies in venture capital financing transactions, including private placements of convertible preferred stock and subordinated debt.
He also represents buyers and sellers in mergers and acquisitions, involving public and private companies. His work in this area includes helping foreign companies to acquire U.S. companies and organize international operations.
Jeffrey plays an active role in the leadership at Foley Hoag, serving on the firm’s Executive Committee, which works to further its strategic goals for client service, diversity, culture and overall growth.
Vesica Health, Inc., a precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer, in its $30.5 million sale to Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics
MDxHealth SA (Nasdaq/Euronext: MDXH), a foreign private issuer, in its acquisition of the OncoType DX Genomic Prostate Score business from Exact Sciences Corporation (Nasdaq: EXAS) for cash and equity consideration of up to $100 million, including a multi-year earn-out arrangement
Satellite Bio, a regenerative medicine company, in raising $110 million in Seed and Series A funding, led by aMoon Growth with participation from prior Seed stage investors
RedShift BioAnalytics Inc., a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, in closing its $20 million Series E Preferred Stock financing
H.I.G. BioHealth Partners and Accelmed Partners as new investors and co-leads in the $52 million upsized Series B financing of digital therapeutics company Click Therapeutics, Inc. (“Click”)
BigVisible Solutions, Inc. in the sale by its shareholders of the business to SolutionsIQ for an undisclosable amount
Pervasis Therapeutics in connection with a sale of substantially all of Pervasis’ assets to a subsidiary of Shire plc
Zosano Pharma Corporation (Nasdaq: ZSAN) in its initial public offering of 4,500,000 shares of its common stock at a price of $11.00 per share
Rinovum Women’s Health, a privately-held, U.S.-based women’s health company, in its Series C funding
Selecta Biosciences, Inc., a biopharmaceutical company founded by Dr. Omid Farokhzad and Professors Robert Langer and Ulrich von Andrian, in various equity financings totaling over $50 million, including most recently a $10 million extension of Series D financing
NeoGraft Technologies, a development-stage medical device company focused on coronary artery disease, in its $11 million Series C financing
scPharmaceuticals, Inc., a biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, in its $16 million Series A venture financing
ArthroMeda, Inc., a developer of medical devices designed to improve surgical outcomes for patients undergoing joint replacement procedures, in its Series B financing
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of drugs to treat cancer and other diseases, on numerous financings, including a $16 million Series B financing
LICENSING & STRATEGIC ALLIANCES
Zosano Pharma Corporation (Nasdaq: ZSAN), a California-based, biotechnology company that is a pioneer in the transdermal drug delivery field, in the negotiation of an agreement with Novo Nordisk A/S to develop a new transdermal presentation of semaglutide
Zosano Pharma Corporation (Nasdaq: ZSAN) in its exclusive licensing agreement with Eli Lilly and Company to develop ZP-PTH -- Zosano’s proprietary formulation of parathyroid hormone 1-34 (PTH) -- using Zosano’s microneedle patch system for the treatment of osteoporosis patients
Translational Therapeutics Inc. as it entered into a strategic licensing agreement with Clavis Pharma ASA of Norway regarding the development and commercialization of a thyroid cancer treatment
Other Publications
Top five things to consider when negotiating an R&D partnership, MASS HIGH TECH (January 17-23, 2005)
Costs and Benefits of Scientific Advisory Boards, FORUM REPORTER - THE NEWSLETTER OF THE MIT ENTERPRISE FORUM OF CAMBRIDGE (February 2004)
Creative Use of Milestones Can Unlock Venture Capital, FORUM REPORTER - THE NEWSLETTER OF THE MIT ENTERPRISE FORUM OF CAMBRIDGE (February 2003)
Honors & Involvement Overview
HONORS
Legal 500 United States: Life Sciences (2026)
Chambers USA: Private Equity: Venture Capital Investment (2018-2026)
Best Lawyers: Venture Capital Law (2007-2027), Corporate Law (2026 - 2027)
Boston's Best Lawyers: Venture Capital Law (2008, 2011)
Endorsed by PLCWhich Lawyer? for Venture Capital and Life Sciences: Commercial and Partnering (2007-2012 Editions)
The Legal 500 US Volume 1 (Corporate & Finance) (2006)
Listed in Super Lawyers - Massachusetts Rising Stars 2005 - Securities, Corporate Finance & IP
LMG Life Sciences
Recognized as 2024 Venture Capital Life Science Star
Listed in 2025 U.S. Firm & Lawyer Rankings for Venture Capital
INVOLVEMENT
Boston Bar Association, Member
Judge, MassChallenge Venture Funds Competition
Judge, Harvard Business School New Venture Competition
Peer Reviewer for the Massachusetts Life Sciences Center Accelerator Loan Program
Other Events
"Life Cycle of a Life Sciences Company," Foley Hoag's Colorado Life Sciences Summit (November 2025)
“Early Stage Financing: What Does It Take To Be One Step Ahead?,” BioPharm America (September 2019)
“How Pharma and VC Collaborations are Changing the Industry,” BioPharm America (September 2018)
“Alternative Financing and Venture Philanthropy,” BioPharm America (September 2017)
“C-Suite: Life in Public,” BioPharm America (September 2016)
“Creating a Clinical-Stage Startup by In-licensing Assets,” BioPharm America (September 2015)
"A Quick Spin Through Spin-Offs," NYSE Life Sciences Industry Peer Exchange (April 2015)
“Large Series A Financings Deconstructed,” BioPharm America (September 2014)
“From Discovery to Early Stage Drug Development: At the Intersection of Academia, Biotech and Pharm,” BioPharma America (September 2013)
“Creating Value with Limited Liability Companies and Asset-Centric Investing,” BIO International Convention (April 2013)
“New Financing Models for Creative Exit Strategies,” BioPharm America (September 2012)
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
